Back to top

Image: Bigstock

Are Investors Undervaluing Astellas Pharma (ALPMY) Right Now?

Read MoreHide Full Article

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.

Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors rely on traditional forms of analysis on key valuation metrics to find stocks that they believe are undervalued, leaving room for profits.

Luckily, Zacks has developed its own Style Scores system in an effort to find stocks with specific traits. Value investors will be interested in the system's "Value" category. Stocks with both "A" grades in the Value category and high Zacks Ranks are among the strongest value stocks on the market right now.

Astellas Pharma (ALPMY - Free Report) is a stock many investors are watching right now. ALPMY is currently holding a Zacks Rank #2 (Buy) and a Value grade of A.

Value investors also use the P/S ratio. The P/S ratio is calculated as price divided by sales. Some people prefer this metric because sales are harder to manipulate on an income statement. This means it could be a truer performance indicator. ALPMY has a P/S ratio of 2.05. This compares to its industry's average P/S of 2.77.

Finally, we should also recognize that ALPMY has a P/CF ratio of 10.66. This metric focuses on a firm's operating cash flow and is often used to find stocks that are undervalued based on the strength of their cash outlook. ALPMY's P/CF compares to its industry's average P/CF of 12.25. Over the past 52 weeks, ALPMY's P/CF has been as high as 19.49 and as low as 8.81, with a median of 10.90.

Value investors will likely look at more than just these metrics, but the above data helps show that Astellas Pharma is likely undervalued currently. And when considering the strength of its earnings outlook, ALPMY sticks out as one of the market's strongest value stocks.

Published in